Insulet (NASDAQ:PODD) Upgraded by StockNews.com to Buy Rating

StockNews.com upgraded shares of Insulet (NASDAQ:PODD) from a hold rating to a buy rating in a report released on Monday morning.

Several other research analysts have also recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday. Sanford C. Bernstein assumed coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock. Raymond James reissued an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research note on Friday. Stifel Nicolaus boosted their target price on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research note on Friday. Finally, Citigroup upped their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and a consensus price target of $289.06.

Insulet Price Performance

Shares of PODD opened at $283.48 on Monday. The company has a market cap of $19.88 billion, a price-to-earnings ratio of 48.96, a price-to-earnings-growth ratio of 3.62 and a beta of 1.23. Insulet has a twelve month low of $160.19 and a twelve month high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a 50 day moving average of $273.33 and a two-hundred day moving average of $248.46.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, analysts predict that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Institutional Investors Weigh In On Insulet

A number of large investors have recently modified their holdings of the company. Blue Trust Inc. grew its position in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the 4th quarter worth $36,000. Venturi Wealth Management LLC lifted its stake in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in shares of Insulet in the fourth quarter valued at about $42,000. Finally, SRS Capital Advisors Inc. lifted its stake in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 56 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.